Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012

NORCROSS, Ga.--(BUSINESS WIRE)--Oct 26, 2012 - Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it will present at the American Association for the Study of Liver Disease (AASLD) Annual Meeting on November 12, 2012, in Boston, MA.

Preclinical data have demonstrated the ability of the Company's lead galectin inhibitor compound, GR-MD-02, to prevent and reverse the formation of fibrosis in animal models of non-alcoholic steatohepatitis (NASH), or fatty liver disease. The presentation at AASLD will extend understanding about the mechanism by which GR-MD-02 improves pathology in NASH, an important unmet medical need.

Details of the presentation are as follows:
Session: NASH: Basic
Time: Monday, November 12, 2012, 8:30 am – 5:30 pm ET
Title: Galectin-3 targeting drugs inhibit multiple pathological pathways leading to improvement of non-alcoholic steatohepatitis (NASH)
Authors: Peter G. Traber and Eliezer Zomer

About NASH
NASH is a common disease of the liver, affecting 9 to 15 million people in the United States. NASH is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with NASH can develop fibrosis, or scarring of the liver, that can lead to cirrhosis, a severe liver disease where transplantation is the only current treatment available.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

 

Contact: Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO, & CMO
ir@galectintherapeutics.com

 

Posted: October 2012

View comments

Hide
(web4)